Journal of Clinical Pediatrics >
Clinical and genetic characterization of 7 pediatric cases with PRKAG2 cardiac syndrome
Received date: 2024-05-09
Accepted date: 2024-07-11
Online published: 2025-02-27
Objective To investigate the clinical and genetic characteristics of PRKAG2 cardiac syndrome (PCS) in Chinese pediatric patients. Methods A retrospective analysis was conducted on the clinical data and genetic testing results of patients diagnosed with PCS at Shanghai Children's Medical Center from September 1999 to October 2022. Results Seven pediatric patients were included in this study, six males and one female, with a median age of onset of 9.0 (3.0-12.0) years. Five patients had varying degrees of left ventricular hypertrophy, four had ventricular preexcitation, two had atrioventricular conduction block, and one experienced sinus arrest.Six variants in the PRKAG2 gene were identified among the seven patients, including two novel mutations (F293V, Q337H). During a median follow-up of 3.0 (2.0-3.8)years, one patient progressed to end-stage heart failure and underwent heart transplantation, one received a pacemaker due to complete atrioventricular block, and two underwent septal reduction therapy for left ventricular outflow obstruction (septal myectomy or septal radiofrequency ablation, respectively). Conclusions PCS is a rare cause of hypertrophic cardiomyopathy in children, often associated with conduction system abnormalities. It is crucial to consider screening for PCS in pediatric patients with hypertrophic cardiomyopathy who present with pre-excitation syndrome or bradyarrhythmias.
YAN Zihang , WANG Yuzhen , CHAN Wenxiu , CHEN Hao , WU Jinjin , CHEN Yiwei , FU Lijun . Clinical and genetic characterization of 7 pediatric cases with PRKAG2 cardiac syndrome[J]. Journal of Clinical Pediatrics, 2025 , 43(3) : 211 -215 . DOI: 10.12372/jcp.2025.24e0459
| [1] | Hu D, Hu D, Liu L, et al. Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease[J]. EBioMedicine, 2020, 54: 102723. |
| [2] | Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis[J]. Hum Mol Genet, 2001, 10(11): 1215-1220. |
| [3] | Porto AG, Brun F, Severini GM, et al. Clinical spectrum of PRKAG2 syndrome[J]. Circ Arrhythm Electrophysiol, 2016, 9(1): e003121. |
| [4] | Arad M, Benson DW, Perez-Atayde AR, et al. Con-stitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy[J]. J Clin Invest, 2002, 109(3): 357-362. |
| [5] | Burwinkel B, Scott JW, Bührer C, et al. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency[J]. Am J Hum Genet, 2005, 76(6): 1034-1049. |
| [6] | Torok RD, Austin SL, Phornphutkul C, et al. PRKAG2 mutations presenting in infancy[J]. J Inherit Metab Dis, 2017, 40(6): 823-830. |
| [7] | Gollob MH, Seger JJ, Gollob TN, et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy[J]. Circulation, 2001, 104(25): 3030-3033. |
| [8] | Akman HO, Sampayo JN, Ross FA, et al. Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase[J]. Pediatr Res, 2007, 62(4): 499-504. |
| [9] | Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2020, 142(25): e558-e631. |
| [10] | Murphy RT, Mogensen J, Mcgarry K, et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history[J]. J Am Coll Cardiol, 2005, 45(6): 922-930. |
| [11] | Laforêt P, Richard P, Said MA, et al. A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis[J]. Neuromuscul Disord, 2006, 16(3): 178-182. |
| [12] | Thevenon J, Laurent G, Ader F, et al. High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations[J]. Europace, 2017, 19(4): 651-659. |
| [13] | Lopez-Sainz A, Dominguez F, Lopes LR, et al. Clinical features and natural history of PRKAG2 variant cardiac glycogenosis[J]. J Am Coll Cardiol, 2020, 76(2):186-197. |
| [14] | Gollob MH, Green MS, Tang AS, et al. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy[J]. Curr Opin Cardiol, 2002, 17(3): 229-234. |
| [15] | Yavari A, Sarma D, Sternick EB. Human γ2-AMPK Mutations[J]. Methods Mol Biol, 2018, 1732: 581-619. |
/
| 〈 |
|
〉 |
